MedTrace Logo

Selenium Replacement and Serum Selenium Level in Severe Sepsis and Septic Shock Patients

NCT01601938 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2016-03-04

No results posted yet for this study

Summary

This study will be performed to determine whether selenium replacement reduces 28-day mortality of severe sepsis and septic shock patients, and to investigate whether selenium replacement contributes differently to the mortality reduction of the patients according to their initial serum selenium level.

Conditions

Interventions

DIETARY_SUPPLEMENT

selenium replacement

Selenium 500 mcg (10 mL) mixed to 230 mL of normal saline will be infused continuously per day (10 mL/hour). Study drugs will be infused for 7 days.

DIETARY_SUPPLEMENT

Placebo

placebo (10 mL) mixed to 230 mL of normal saline will be infused continuously per day (10 mL/hour). Study drugs will be infused for 7 days.

Sponsors & Collaborators

  • Biosyn

    collaborator INDUSTRY

  • Boryung Pharmaceutical Co., Ltd

    collaborator INDUSTRY

  • Gil Joon Suh

    lead OTHER

Principal Investigators

  • Gil Joon Suh, professor · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2014-04-30
Completion
2014-05-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01601938 on ClinicalTrials.gov